Shots:
- The EC has approved Bysumlog & Dazparda, the biosimilar versions of Humalog (insulin lispro) & NovoRapid (insulin aspart), respectively, as prefilled pens
- Bysumlog is approved for the treatment and initial stabilisation of diabetes mellitus in adults & children, while Dazparda is approved for diabetes treatment in pts (≥1yr.). Both demonstrated equivalent efficacy & comparable safety to their reference medicines
- In 2018, Sandoz entered an agreement with Gan & Lee to commercialize biosimilar insulin aspart, lispro, & glargine products, with Sandoz holding commercialization rights across EU & other key global markets, while Gan & Lee managing development, manufacturing, & supply
Ref: Sandoz | Image: Sandoz | Press Release
Related News: Samsung Bioepis Partners with Sandoz for Up to Five Biosimilar Candidates
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
